Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Contemp Clin Trials ; 102: 106283, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33484897

RESUMEN

BACKGROUND: Uncontrolled or undiagnosed hypertension (HTN) is estimated to be as high as 46% in emergency departments (EDs). Uncontrolled HTN contributes significantly to cardiovascular morbidity and disproportionately affects communities of color. EDs serve high risk populations with uncontrolled conditions that are often missed by other clinical settings and effective interventions for uncontrolled HTN in the ED are critically needed. The ED is well situated to decrease the disparities in HTN control by providing a streamlined intervention to high risk populations that may use the ED as their primary care. METHODS: Targeting of UnControlled Hypertension in the Emergency Department (TOUCHED), is a two-arm single site randomized controlled trial of 770 adults aged 18-75 presenting to the ED with uncontrolled HTN comparing (1) usual care, versus (2) an Educational and Empowerment (E2) intervention that integrates a Post-Acute Care Hypertension Consultation (PACHT-c) with a mobile health BP self-monitoring kit. The primary outcome is differences in mean systolic blood pressure (SBP) at 6-months post enrollment. Secondary outcomes include differences in mean SBP and mean diastolic BP (DBP) at 3-months and mean DBP at 6-months. Additionally, improvement in cardiovascular risk score, medication adherence, primary care engagement, and HTN knowledge will also be assessed as part of this study. CONCLUSIONS: The TOUCHED trial will be instrumental in determining the effectiveness of a brief ED-based intervention that is portable to other urban EDs with high-risk populations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT03749499.


Asunto(s)
Hipertensión , Telemedicina , Adulto , Antihipertensivos/uso terapéutico , Presión Sanguínea , Servicio de Urgencia en Hospital , Humanos , Hipertensión/tratamiento farmacológico , Cumplimiento de la Medicación
2.
Health Promot Pract ; 22(5): 714-723, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-32552138

RESUMEN

Background. Uncontrolled hypertension is the primary risk factor for the development of cardiovascular complications and particularly burdens racial/ethnic minority populations. Aim. To determine the effectiveness of a community hypertension screening, education, and empowerment intervention on blood pressure (BP) improvement. Method. We screened 152 participants across four churches in predominantly racial/ethnic minority neighborhoods for elevated BP. During this visit, those with BP ≥ 140/90 mmHg were enrolled in the study and completed interventions. Individuals with moderately elevated BP (≥140/90 and <160/100 mmHg; Group 1) viewed a 3-minute hypertension education video. Individuals with severely elevated BP (≥160/100 mmHg; Group 2) additionally viewed echocardiograms images with subclinical changes from uncontrolled hypertension and had a brief on-site medication review with a pharmacist. Both groups received automated BP monitors and information on neighborhood federally qualified health centers for primary care. Participants returned to each church for follow-up 3 months later. We analyzed BP difference at 3 months and percentage with controlled BP for each group. Results. For Group 1, mean baseline and follow-up BPs were 143.5/88.0 mmHg and 138.5/85.8 mmHg, respectively. For Group 2, BPs significantly decreased from 165.4/98.3 mmHg to 150.4/90.8 mmHg. After the intervention, participants with controlled BP for Groups 1 and 2 were 35.5% and 55.2%, respectively. Discussion. Participants in both groups had BP improvements. Greater improvements were in individuals at higher cardiovascular risk due to severely elevated BPs (≥160/100 mmHg). Conclusion. This pilot highlights the impact that streamlined empowerment interventions with dedicated health personnel can have in high-risk communities with elevated BPs.


Asunto(s)
Etnicidad , Hipertensión , Negro o Afroamericano , Antihipertensivos/uso terapéutico , Presión Sanguínea , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Grupos Minoritarios
3.
Contemp Clin Trials ; 64: 1-7, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29128648

RESUMEN

Effective interventions to identify and treat uncontrolled hypertension (HTN), particularly in underrepresented populations that use the emergency department (ED) for primary care, are critically needed. Uncontrolled HTN contributes significantly to cardiovascular morbidity and mortality and is more frequently encountered among patients presenting to the ED as compared to the primary care setting. EDs serve as the point of entry into the health care system for high-risk patient populations, including minority and low-income patients. Previous studies have demonstrated that the prevalence of uncontrolled/undiagnosed HTN in patients presenting to the ED is alarmingly high. Thus ED engagement and early risk assessment/stratification is a feasible innovation to help close health disparity gaps in HTN. A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities (AHEAD2) trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) is a three-arm single site randomized clinical pilot trial of adults presenting to the ED with Stage 2 hypertension (blood pressure [BP]>160/100) comparing (1) an ED-initiated Screening, Brief Intervention, and Referral for Treatment (SBIRT) focused on HTN, (2) the same ED-initiated SBIRT coupled with a Post-Acute Care Hypertension Transition Consultation by ED Clinical Pharmacists, and (3) usual care. The primary outcome is mean BP differences between study arms. Secondary outcomes are proportion of participants with BP control (BP<140/90mmHg), and improvements in HTN knowledge and medication adherence scores between study arms. The objective of this report is to describe the development of the AHEAD2 trial, including the methods, research infrastructure, and other features of the randomized clinical trial design.


Asunto(s)
Servicio de Urgencia en Hospital/organización & administración , Disparidades en el Estado de Salud , Hipertensión/diagnóstico , Hipertensión/etnología , Grupos Minoritarios , Adulto , Antihipertensivos/uso terapéutico , Presión Sanguínea , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Hipertensión/tratamiento farmacológico , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Atención Primaria de Salud , Derivación y Consulta , Medición de Riesgo , Factores de Riesgo
4.
Ann Pharmacother ; 47(11): 1577-80, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24259597

RESUMEN

OBJECTIVE: To report a case of sustained hypotension associated with the use of intravenous metoclopramide. CASE SUMMARY: A 50-year-old woman developed a hypotensive episode lasting approximately 90 minutes after the administration intravenous metoclopramide for the treatment of a migraine. The patient presented to the emergency department after she woke up with a severe headache that was much worse than her normal migraine headaches. Her past medical history included migraines, diabetes type 2, hypertension, and hyperlipidemia. Fifteen minutes after the administration of intravenous metoclopramide 10 mg, the patient's systolic blood pressure decreased from 138 to 84 mmHg (a mean arterial pressure decrease of 40.7 mmHg). The patient was given 1 L of intravenous NaCl 0.9% that had minimal effect on blood pressure. The patient did not reapproach her baseline systolic blood pressure until 90 minutes after the metoclopramide administration when it was measured at 138 mmHg. Subsequent contrast tomography of the head was negative and the patient's headache was successfully treated with butalbital/acetaminophen/caffeine. The patient was discharged home the same day. DISCUSSION: There are few published case reports of metoclopramide-induced hypotension in the current literature. Of those published, all showed transient hypotension with metoclopramide, lasting seconds to minutes. An objective causality assessment for drug-associated adverse drug reaction showed metoclopramide as a probable cause of the patient's hypotension (Naranjo score of 5). In this case, several indicators of metoclopramide induced hypotension were evident, including the timing of the hypotension after drug administration and the lack of any other possible causes of hypotension. This is the first published case report of sustained hypotension due to intravenous metoclopramide. CONCLUSION: Intravenous metoclopramide may cause sustained episodes of hypotension.


Asunto(s)
Antagonistas de Dopamina/efectos adversos , Hipotensión/inducido químicamente , Metoclopramida/efectos adversos , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/uso terapéutico , Femenino , Humanos , Hipotensión/diagnóstico , Hipotensión/tratamiento farmacológico , Metoclopramida/administración & dosificación , Metoclopramida/uso terapéutico , Persona de Mediana Edad , Trastornos Migrañosos/tratamiento farmacológico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...